Skip to main content
. 2021 Dec 30;15(1):48. doi: 10.3390/ph15010048

Figure 1.

Figure 1

Alternate mechanisms of JAK inhibition. Deucravacitinib inhibits TYK2 activation by interacting with the pseudokinase (JH2) domain (allosteric inhibition), while first-generation jakinibs inhibit enzymatic activity by binding to the ATP-binding (JH1) domain (competitive inhibition).